Comparing ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) (Covishield) and BBV152; Bharat Biotech COVID-19 Vaccine (Covaxin) for COVID-19: Reports of Adverse Events Following Vaccination among the Indian Population
Our study observed that both ChAdOx1 nCoV-19 and BBV152 have a favorable safety profile without serious AEFIs in any of the beneficiaries.
Authors
- Choro Athiphro Kayina (ORCID: https://orcid.org/0000-0003-3509-5508)
- Shiv Lal Soni (ORCID: https://orcid.org/0000-0002-8334-1868)
- Jasvir Kaur (ORCID: https://orcid.org/0000-0002-2351-2856)
- Sukhpal Kaur (ORCID: https://orcid.org/0000-0003-3724-1310)
- Latika Rohilla (ORCID: https://orcid.org/0000-0001-9803-779X)
- Anjani Walia
- Gurpreet Kaur (ORCID: https://orcid.org/0000-0002-2769-3594)
- Ajay Kumar Singh (ORCID: https://orcid.org/0000-0001-6160-8376)
- Pramod Kumar
- Sushma Kumari Saini
Institutions
- All India Institute of Medical Sciences Bhopal (IN)
- Post Graduate Institute of Medical Education and Research (IN)
- All India Institute of Medical Sciences (IN)
Publication Details
- Journal
- Indian Journal of Public Health
- Published
- 2025-01-01
- DOI
- https://doi.org/10.4103/ijph.ijph_505_23
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.40